[go: up one dir, main page]

MX2021003116A - Profarmacos macromoleculares a base de polimero. - Google Patents

Profarmacos macromoleculares a base de polimero.

Info

Publication number
MX2021003116A
MX2021003116A MX2021003116A MX2021003116A MX2021003116A MX 2021003116 A MX2021003116 A MX 2021003116A MX 2021003116 A MX2021003116 A MX 2021003116A MX 2021003116 A MX2021003116 A MX 2021003116A MX 2021003116 A MX2021003116 A MX 2021003116A
Authority
MX
Mexico
Prior art keywords
polymer
prodrugs
based macromolecular
macromolecular prodrugs
macromoiecular
Prior art date
Application number
MX2021003116A
Other languages
English (en)
Inventor
Ivan Alferiev
Michael Chorny
Garrett M Brodeur
Original Assignee
Childrens Hospital Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Philadelphia filed Critical Childrens Hospital Philadelphia
Publication of MX2021003116A publication Critical patent/MX2021003116A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Se proporcionan profármacos macromoleculares en los que los análogos de camptotecina se unen covalentemente a polímeros mediante enlaces éster que son lábiles en condiciones fisiológicas. También se proporcionan métodos para tratar el cáncer, especialmente el neuroblastoma con profármacos macromoleculares.
MX2021003116A 2018-09-17 2019-09-17 Profarmacos macromoleculares a base de polimero. MX2021003116A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862732199P 2018-09-17 2018-09-17
PCT/US2019/051457 WO2020061007A1 (en) 2018-09-17 2019-09-17 Polymer-based macromolecular prodrugs

Publications (1)

Publication Number Publication Date
MX2021003116A true MX2021003116A (es) 2021-05-14

Family

ID=69887739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003116A MX2021003116A (es) 2018-09-17 2019-09-17 Profarmacos macromoleculares a base de polimero.

Country Status (11)

Country Link
US (3) US11253603B2 (es)
EP (1) EP3852793A4 (es)
JP (1) JP7546552B2 (es)
KR (1) KR20210072002A (es)
CN (1) CN112996533B (es)
AU (1) AU2019344783A1 (es)
CA (1) CA3112778A1 (es)
EA (1) EA202190799A1 (es)
MX (1) MX2021003116A (es)
NZ (1) NZ773863A (es)
WO (1) WO2020061007A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852793A4 (en) 2018-09-17 2022-07-13 The Children's Hospital Of Philadelphia Polymer-based macromolecular prodrugs
CN115443947B (zh) * 2022-10-12 2023-11-21 江苏省人民医院（南京医科大学第一附属医院） 高血压动物模型的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3406599A (en) * 1998-04-09 1999-11-01 Institut Fur Diagnostikforschung Gmbh An Der Freien Universitat Berlin Novel benzyl guanidine derivatives for therapy and (in-vivo) and (in-vitro) diagnosis
JP2002255821A (ja) * 2001-03-06 2002-09-11 Yakult Honsha Co Ltd 抗癌剤耐性癌に対する治療剤
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US20040258754A1 (en) * 2003-06-18 2004-12-23 Valery Alakhov Compositions for oral administration of camptothecin and its analogs
PT1675622T (pt) 2003-09-17 2017-09-19 Nektar Therapeutics Pró-fármacos de polímeros de múltiplos braços
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1682552B1 (en) * 2003-10-29 2010-06-30 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
US20070254019A1 (en) * 2006-03-15 2007-11-01 William Zamboni Method for treating brain cancer
US20090074074A1 (en) 2007-06-29 2009-03-19 The Hong Kong University Of Science And Technology Multiple description encoder and decoder for transmitting multiple descriptions
US8637466B2 (en) * 2008-08-11 2014-01-28 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
EP2349346B1 (en) 2008-09-23 2019-08-28 Nektar Therapeutics Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
AU2009307922A1 (en) * 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
CN101385860B (zh) * 2008-10-31 2011-11-02 美国草药泉有限责任公司 喜树碱及其衍生物的非线性聚乙二醇前药
BR112012001395A2 (pt) 2009-07-22 2019-09-24 Enzon Pharmaceuticals Inc metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero
AU2010321882B2 (en) 2009-11-18 2016-01-14 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
WO2012083197A1 (en) 2010-12-17 2012-06-21 Nektar Therapeutics Water-soluble polymer conjugates of topotecan
CN102626518B (zh) * 2012-05-09 2014-05-28 中国药科大学 一种包载难溶性药物的泊洛沙姆/两亲性多糖混合胶束的制备和应用
KR102120510B1 (ko) 2012-11-28 2020-06-08 넥타르 테라퓨틱스 지속 작용성 토포아이소머라제 i 저해제를 이용하는 유방암 치료의 효능을 평가 및 예측하기 위한 방법
US9863949B2 (en) 2013-05-31 2018-01-09 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents
EP3052101B1 (en) * 2013-10-04 2019-11-20 Prolynx LLC Slow-release conjugates of sn-38
US10758614B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016050210A1 (zh) 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 一种多官能化聚乙二醇衍生物及其制备方法
CN104877127B (zh) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
CN107375288B (zh) 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
US20200163956A1 (en) 2016-09-06 2020-05-28 Cerebral Therapeutics LLC Direct brain administration of chemotherapeutics to the csf for patients with primary and secondary brain tumors
US11191843B2 (en) 2017-04-21 2021-12-07 Brightgene Bio-Medical Technology Co., Ltd. Multi-arm targeting anti-cancer conjugate
WO2019051246A1 (en) 2017-09-08 2019-03-14 Phosplatin Therapeutics Llc PHOSPHAPLATINE COMPOUNDS AS IMMUNOMODULATORS AND THERAPEUTIC USES THEREOF
WO2019090141A1 (en) 2017-11-02 2019-05-09 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
AU2019271129B2 (en) 2018-05-14 2023-03-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP3852793A4 (en) * 2018-09-17 2022-07-13 The Children's Hospital Of Philadelphia Polymer-based macromolecular prodrugs
CN111603567B (zh) 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
BR112021022008A2 (pt) 2019-05-14 2022-05-17 Nuvation Bio Inc Compostos de direcionamento a receptor de hormônio nuclear anticâncer

Also Published As

Publication number Publication date
JP7546552B2 (ja) 2024-09-06
JP2022501341A (ja) 2022-01-06
US11253603B2 (en) 2022-02-22
CA3112778A1 (en) 2020-03-26
EP3852793A1 (en) 2021-07-28
KR20210072002A (ko) 2021-06-16
EP3852793A4 (en) 2022-07-13
US20220160886A1 (en) 2022-05-26
NZ773863A (en) 2024-10-25
AU2019344783A1 (en) 2021-04-08
CN112996533A (zh) 2021-06-18
CN112996533B (zh) 2025-01-10
US11642414B2 (en) 2023-05-09
US20230414766A1 (en) 2023-12-28
EA202190799A1 (ru) 2021-06-22
US20210000967A1 (en) 2021-01-07
WO2020061007A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
PH12020550805A1 (en) Exosomes for immuno-oncology and anti-inflammatory therapy
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
PH12016501411B1 (en) Bifunctional cytotoxic agents
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
PH12016501680B1 (en) Anti-egfrviii antibodies and uses thereof
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX367853B (es) Ácido hialurónico entrelazado injertado con dextrán.
PH12017502216A1 (en) Nucleic acid-cationic polymer compositions and methods of making and using the same
MX2016004596A (es) Conjugados de proteina-polimero-farmaco.
MX2016004659A (es) Conjugados proteina-polimero-farmaco.
BR112018015836A2 (pt) administração de células t engenheiradas para tratamento de cânceres no sistema nervoso central
UY36075A (es) Derivados de tubulisina
MX2018001511A (es) Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
MX2023002599A (es) Conjugados de compuestos de tubulisina cuaternizada.
TN2016000472A1 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
MX2018008321A (es) Tratamiento de tumores ocasionados por disfuncion metabolica.
MX2022003217A (es) Conjugados terapeuticos.
BR112015023342A2 (pt) resinas acopladas radicalmente e métodos para preparar e usar as mesmas
NZ773863A (en) Polymer-based macromolecular prodrugs
MX2020007393A (es) Compuestos de fósforo(n)amidatacetal y fosf(on)atalcetal.
WO2015169811A3 (en) Anti-cxc chemokine receptor-2 binding molecules and uses thereof
TW201613650A (en) FVIII conjugates